Skip to main content
. 2016 Nov 21;7(50):82123–82138. doi: 10.18632/oncotarget.13488

Figure 2. Monitoring and analysis of PTX3 levels in the plasma of HSCT pediatric patients.

Figure 2

A. Available PTX3 plasma levels measured on 115 patients before the beginning of conditioning regimen (basal), on day 0 (HSCT) and weekly until day +100 for patients not experiencing GvHD, or until disease occurrence for GvHD patients. B. Relative change (RC) of PTX3 concentration over baseline at day 0 in 96 patients where both measurements could be performed. RC was calculated as follows: day 0 RC = (day 0 PTX3- basal PTX3/basal PTX3). The p-value indicates that RC at HSCT is significantly different from zero. C. PTX3 RC at day 0 measured according to the intensity of the conditioning regimen, D. the type of donor (RD = related donor, URD = unrelated donor), and E. the HLA-matching in the donor/recipient pair (HLA-matched = matching ≥9/10 in the case of bone marrow or peripheral blood; = 6/6 in the case of cord blood). Each box-plot shows the median, the first and third quintiles and extends from the lowest to the highest value; extreme outliers are not shown, but were included in the calculations.